A STUDY OF THE PKMYT1 INHIBITOR RP-6306 IN COMBINATION WITH CARBOPLATIN AND PACLITAXEL FOR TREATMENT OF RECURRENT TP53 OVARIAN AND UTERINE CANCER (GYNEREP)
PHASE 1/2 (21-DAY CYCLE)
6 CYCLES ONLY
FOLLOW UP
Alas…the trial is now complete and I am at my first follow-up appointment.
CA125 decreased by 700! That's an overall decrease of over 95% after 6 cycles! I have not had such a low CA125 count since 2022!
NEXT STEPS
CT scan reports more than 30% decrease in my tumours which is classified as "partial response." YAY!! However, there is a discrepancy between the PMH Tech and Trial Tech reports. The PMH Tech reported new growth but the Trial Tech did not and the Drs did not see new growth when they reviewed my scans. So, The Techs have been asked to confer and return a consensus on whether or not there is new growth. This will be the determining factor in how I move forward from here.
Move forward: If no new growth = chemo holiday!! If it is indeed a new growth, that would indicate progression and I would be eligible for another trial and will explore that option with my care team. The other option will be to return to standard of care drugs – the next one for me is Gemcitabine.